Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing

News
Video

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Related Videos
A panel of 5 experts on lung cancer seated at a long table
A panel of 5 experts on lung cancer seated at a long table
Jason Porter, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Experts on RCC
Related Content
Lyudmila A. Bazhenova, MD

Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC

November 30th 2023
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
Biagio Ricciuti, MD

Long-Term Survival Benefit With PD-1 Monotherapy Correlated With High PD-L1 Expression in Advanced NSCLC

November 29th 2023
Article
Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP

Expert Insights on the United States Chemotherapy Shortage

October 9th 2023
Podcast
Yu Wang, MD, PhD, chief medical officer of GenFleet

IBI351 NDA Under NMPA Review in Advanced KRAS G12C–Mutant NSCLC

November 28th 2023
Article
Konstantinos Arnaoutakis, MD

Increasingly Specialized Clinical Trials Accelerate Advances in NSCLC Management

November 27th 2023
Article